Regeneron Pharmaceuticals (REGN)
EBITDA Margin
37.01%
TTM · Period ending:
REGN EBITDA Margin
Latest reported37.01%period ending
Latest reported37.01%period ending
REGN TTM EBITDA Margin (-66.00% → 37.01%)
TTM ebitda margin
High-resolution chart · PNG
REGN ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -106.9308% | |
| -66.9962% | |
| -55.5672% | |
| -47.3802% | |
| -29.8854% | |
| -48.1186% | |
| -61.2717% | |
| -89.3688% | |
| -82.4324% | |
| -41.3978% | |
| -25.3927% | |
| -4.5024% | |
| -0.7444% | |
| -12.8743% | |
| -9.6677% | |
| -29.7872% | |
| -43.9216% | |
| -43.4263% | |
| -46.473% | |
| -41.453% | |
| -32.4786% | |
| -20.9677% | |
| -9.434% | |
| -17.6056% | |
| -21.865% | |
| -59.0406% | |
| -107.7586% | |
| -170.6522% | |
| -284.7328% | |
| -346.2963% | |
| -367.6768% | |
| -339.7849% | |
| -348.1481% | |
| -221% | |
| -143.8596% | |
| -128.8288% | |
| -108.4906% | |
| -113.1868% | |
| -72.3684% | |
| -131.8841% | |
| -87.3016% | |
| -43.1034% | |
| -66% |